Supply of Blood Components and Products

The contract entails the supply of whole blood and its derived components—including red blood cells, platelets, plasma, and cryoprecipitate—to Veterans Affairs medical centers, requiring full compliance with FDA and AABB standards throughout every stage of collection, testing, processing, and labeling. All activities must adhere to rigorous quality and safety protocols to ensure the integrity and suitability of blood products for patient transfusion, with strict attention to inventory management, chain of custody, and product traceability. The successful bidder must demonstrate consistent capacity to meet the VA’s operational demands while maintaining compliance with federal regulations and industry best practices. This subcontract is issued under the 252-NETWORK Contract Office 12 (36C255) of the Department of Veterans Affairs and falls under NAICS code 325414, which designates the manufacturing of biological products, excluding pharmaceuticals. The opportunity was posted on July 22, 2026, with a firm response deadline of August 21, 2026, at 5:00 p.m. The place of performance and specific delivery locations are not detailed in the provided data, but fulfillment is expected to support VA facilities nationwide. The contract requires a robust logistical and manufacturing infrastructure to handle the time-sensitive nature of blood component distribution while ensuring seamless integration into VA’s existing transfusion services.